PdH nanozymes have exhibited multienzyme activity and have been commonly used in therapies for atherosclerosis and Alzheimer's disease.[24, 25] Aptamer‐functionalized nanozymes have been developed as targeted therapies for tumors and regeneration medicine.[26, 27] In this study, we developed aptamer nanoplatforms bridged with PdH nanozymes for targeted recruitment and autocatalytic therapies. The gene discussed is PDP1; the disease is early-onset autosomal dominant Alzheimer disease.